cpgj602
mAbexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 15, 2017 (NCT03356158)
Timeline
Indications
Studied for
Mechanism of action
EGFR inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04466254 | Phase 2 | Aug 4, 2020 | Sunshine Lake Pharma Co., Ltd. |
| NCT03356158 | Phase 1 | Nov 15, 2017 | People's Liberation Army of China, Sunshine Lake Pharma Co., Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sunshine Lake Pharma Co., Ltd. | For profit | 2 | 2 | 2 | 2017 |
| People's Liberation Army of China | Government | 1 | 0 | 1 | 2017 |
2 organizations
Page 1 / 1